GlassScriptPhysician profile
Michael K Davenport
NPI 1710982517
$27,153.49
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $1,534 · 2021: $2,583 · 2022: $2,633 · 2023: $5,072 · 2024: $1,414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,000 · Education: $2,000 · Food and Beverage: $1,486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,000.00 |
| Education | $2,000.00 |
| Food and Beverage | $1,485.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $23,899.64 | 2019-2024 | Da Vinci Surgical System, Da Vinci Sp |
| Davol INC. | $1,489.14 | 2019-2024 | Phasix Mesh |
| Conmed Corporation | $313.82 | 2020-2024 | Airseal |
| Allergan, INC. | $203.85 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $132.36 | 2021-2023 | Gattex |
| W. L. Gore & Associates, INC. | $127.19 | 2021-2024 | Gore Synecor Biomaterial |
| Tela Bio, INC. | $111.48 | 2022-2024 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| Becton, Dickinson and Company | $97.99 | 2021 | |
| Ethicon US, LLC | $96.47 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $77.71 | 2019-2022 | |
| Heron Therapeutics, INC. | $62.20 | 2021-2024 | Zynrelef, Aponvie |
| Innocoll Pharmaceuticals Limited | $58.60 | 2021-2022 | |
| Endologix LLC | $50.49 | 2021 | |
| Smith+Nephew, INC. | $45.63 | 2019 | |
| Melinta Therapeutics, LLC | $43.64 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $40.09 | 2021-2022 | |
| Convatec INC. | $33.68 | 2019-2023 | |
| Hologic Sales and Service, LLC | $33.58 | 2023 | Coolseal Generator |
| Abbvie INC. | $31.66 | 2023 | Dalvance, Strattice Reconstructive Tissue Matrix Bps |
| Cumberland Pharmaceuticals, INC. | $25.63 | 2019-2020 | |
| Pacira Pharmaceuticals Incorporated | $24.11 | 2022 | |
| Misonix INC | $22.72 | 2020 | |
| Shire North American Group INC | $20.35 | 2019 | |
| Medtronic, INC. | $17.65 | 2024 | Progrip |
| Mimedx Group, INC. | $17.52 | 2024 | |
| Chiesi USA, INC. | $16.30 | 2021 | |
| Solventum Corporation | $13.31 | 2024 | V.A.C. Veraflo Cleanse Choice, Prevena |
| Coopersurgical, INC. | $12.54 | 2019 | |
| Acell, INC. | $11.60 | 2019 | |
| Triad Life Sciences INC. | $11.27 | 2021 | |
| Paratek Pharmaceuticals, INC. | $11.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Davenport listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.